KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) EPS (Weighted Average and Diluted) (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed EPS (Weighted Average and Diluted) for 15 consecutive years, with -$0.07 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 125.93% to -$0.07 in Q4 2025 year-over-year; TTM through Dec 2025 was -$0.68, a 151.52% decrease, with the full-year FY2025 number at -$0.68, down 151.52% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.07 for Q4 2025 at Supernus Pharmaceuticals, up from -$0.8 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.69 in Q3 2024 to a low of -$0.8 in Q3 2025.
  • A 5-year average of $0.13 and a median of $0.12 in 2021 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): soared 2669.85% in 2024, then tumbled 8268.95% in 2025.
  • Supernus Pharmaceuticals' EPS (Weighted Average and Diluted) stood at $0.04 in 2021, then skyrocketed by 950.0% to $0.42 in 2022, then plummeted by 95.24% to $0.02 in 2023, then skyrocketed by 1250.0% to $0.27 in 2024, then tumbled by 125.93% to -$0.07 in 2025.
  • Per Business Quant, the three most recent readings for SUPN's EPS (Weighted Average and Diluted) are -$0.07 (Q4 2025), -$0.8 (Q3 2025), and $0.4 (Q2 2025).